Trade Desk (TTD) Could Be 59% Undervalued As OptimizeRx Expands Healthcare Reach

Trade Desk’s healthcare push through OpenPath and OptimizeRx

Trade Desk (TTD) is back in focus after OptimizeRx announced an integration with OpenPath, the firm’s supply path optimization tool, to pipe authenticated point of care healthcare inventory directly into its demand side platform.

For context, Trade Desk shares have declined 17.2% over the past 30 days and are down 68.3% on a year to date share price basis, while the 1 year total shareholder return has fallen 76.8%. As a result, investors are treating new partnerships like OptimizeRx as potential tests of whether sentiment can stabilise or if concerns around growth and risk remain in control.

Scan beyond Trade Desk and stress test this healthcare advertising theme against a curated set of 35 healthcare AI stocks that are also plugged into medical data and clinical workflows.

Trade Desk now trades far below its recent levels after a sharp reset. The real tension is whether this pullback leaves meaningful upside ahead or if the bulk of the story already sits in the rearview mirror.

Most Popular Narrative: 59.1% Undervalued

Trade Desk closed at $11.95 while the most followed narrative pegs fair value at $29.24, which frames the recent share slide as a valuation reset that some investors see as excessive.

Basically this is a stock that has bottomed out and has seen significant increased competition and resourcing challenges. Unless there are significant partnerships and new endeavours, there may be limited drivers for its growth outside of rapidly expanding global marketplace endeavours, as 82% of revenue comes from the US.

See why 24 investors see Trade Desk as 59% undervalued.

Result: Fair Value of $29.24 (UNDERVALUED)

Still, the Trade Desk narrative could break if competition from larger DSPs accelerates, or if revenue growth remains weak despite new tools and partnerships.

Find out about the key risks to this Trade Desk narrative.

Next Steps

With Trade Desk sentiment pulled in two directions by fresh partnerships and a sharp share reset, this is the moment to pressure test the numbers yourself, weigh both sides of the story, and see how the current mix of concern and optimism shows up in the 1 key reward and 1 important warning sign.

Looking for more Trade Desk investment ideas?

If Trade Desk has you rethinking your watchlist, this is the point to widen the lens and hunt for other opportunities before the crowd catches up.

• Target underappreciated quality and let the screener surface companies that look mispriced on fundamentals through the 31 high quality undervalued stocks.
• Strengthen your downside protection by focusing on balance sheet resilience with a curated list of solid balance sheet and fundamentals (25 results).
• Hunt for earlier stage opportunities that still clear basic quality filters using the 8 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com